Organism: human
Disease: COVID-19
Sex: male
Age: >=18 years
MaterialType: plasma
MaterialType: platelets
MaterialType: lysate
SampleTreatment: citrate-anticoagulated blood
SampleTreatment: frozen at -196 °C
SampleTreatment: stored at -80 °C
SampleTreatment: resuspended in urea buffer (7 M urea, 2 M thiourea, 50 mM Tris)
SampleTreatment: reduction with 10 mM DTT
SampleTreatment: alkylation with 15 mM iodoacetamide
SampleTreatment: precipitated with acetone
SampleTreatment: digested with trypsin
SampleTreatment: stopped with 0.1% trifluoroacetic acid
SampleTreatment: sonicated
ReductionReagent: dithiothreitol
AlkylationReagent: iodoacetamide
CleavageAgent: trypsin
Label: carbamidomethylation (cysteine)
Label: oxidation (methionine)
Modification: oxidation (methionine)
Compound: trifluoroacetic acid
Compound: urea
Compound: thiourea
AssayName: label-free proteomics
AssayName: LC-MS/MS
AssayName: parallel reaction monitoring mass spectrometry (PRM-MS)
AssayName: ELISA
Instrument: Orbitrap Fusion Lumos Tribrid Mass Spectrometer
IonizationType: electrospray ionization
AcquisitionMethod: data-dependent acquisition (DDA)
AcquisitionMethod: parallel reaction monitoring (PRM)
FragmentationMethod: higher-energy collisional dissociation (HCD)
CollisionEnergy: 28% normalized collision energy
MS2MassAnalyzer: Orbitrap
PrecursorMassTolerance: 4.5 ppm
PrecursorMassTolerance: 20 ppm
FragmentMassTolerance: 20 ppm
Separation: trap column (Acclaim PepMap 100, 300 μm x 5 mm, C18)
Separation: analytical column (75 μm x 50 cm, C18)
Separation: gradient 5% to 30% solvent B over 98 min
FlowRateChromatogram: 400 nL/min
FlowRateChromatogram: 30 μL/min
NumberOfMissedCleavages: 2
FactorValue: clinical outcome (ICU A, ICU B, NW, Control)
NumberOfSamples: 19 ICU patients
NumberOfSamples: 5 NW patients
NumberOfSamples: 16 controls
TechnicalReplicate: system suitability monitored with replicate A549 digest injections